Zantac and products containing ranitidine were removed from the United States market in 2020 at the request of the FDA. The reason why was the medication was found to be contaminated by NDMA, which is classified as a probable carcinogen by the EPA and IARC.
In fact, lab testing has even found that NDMA literally forms by itself in Zantac over time when the drug is exposed to heat.
Nadrich & Cohen is representing those who have developed cancer after using Zantac. We represent Zantac victims on a contingency fee basis. This means that we will not charge you a fee until and unless we recover financial compensation for you.
Call us today for a free consultation, text us from this page or fill out the free case evaluation form on this page if you or a loved one developed cancer after taking Zantac.
Zantac Lawsuit 2023 Latest News And Updates
- Many of the cases in the Zantac MDL have seen dismissal. However, nearly 15,000 lawsuits are still pending on appeal as of August 15, 2023.
- On June 30, 2023, Reuters reported that the first trial in the United States over the allegations that Zantac can cause cancer is scheduled to take place on November 13, 2023 in a California state court. It is estimated that about 70,000 lawsuits over the drug are pending in various state courts across the nation.
- On June 23, 2023, GSK announced that it had reached settlement, the amount of which is confidential, with a plaintiff who had filed a lawsuit in California state court alleging that Zantac caused his bladder cancer.
- On March 23, 2023, a judge in Alameda County evaluated the reliability of scientific evidence regarding the risks of cancer associated with Zantac. The judge issued a ruling, determining that expert witnesses which had been proposed by the plaintiffs will be able to participate in Zantac litigation, allowing a Zantac case to proceed.
- In February 2023, Bloomberg Law reported that, according to court records as well as other documents, GSK knew that Zantac may cause cancer for decades, yet failed to warn the public about this. The report highlighted scientists who worked with GSK suspecting since the late 1970s that ranitidine could cause cancer.
- On December 6, 2022, a federal judge dismissed all federal Zantac cases. This decision, however, did not dismiss thousands of lawsuits which had been filed in state courts.
- In September 2022, researchers published a study looking into the cancer risks associated with Zantac. The researchers found that the drug was linked with a 35 percent increase in pancreatic cancer risk, a 26 percent increase in gastric cancer risk, a 22 percent increase in liver cancer risk and a 17 percent increase in lung cancer risk.